Daily Market BriefHealthcare

Big Pharma Upgrades & Abbott Settlement Lead Friday Action

Merck receives mixed analyst calls, Abbott settles preterm formula litigation for ~$670M, while biotech sector shows sustained momentum

Money365.Market AI
2 min read
Market MoodMixed
Sentiment+15Mixed

Key DriverMixed analyst activity on major pharma names and significant litigation settlement drive sector focus

Today in 30 Seconds

  • Abbott settles preterm infant formula litigation involving ~2,000 individuals for $670M
  • Merck receives conflicting analyst calls: Morgan Stanley upgrade, RBC downgrade
  • Biotech sector momentum continues with SPDR S&P Biotech ETF up 34% since March
All Briefs

Big Pharma Analyst Activity

Neutral

Merck PT (BMO)

$170+from $142

Amgen PT (Piper)

$457+from $427

AbbVie PT (Piper)

$303+from $298
$MRK$AMGN$ABBV

Merck & Co. ($MRK) received divergent analyst calls, with Morgan Stanley upgrading the stock while RBC Capital issued a downgrade. BMO Capital maintained an Outperform rating and raised its price target to $170 from $142. Separately, Amgen ($AMGN) saw Piper Sandler maintain its Overweight rating while raising the price target to $457 from $427, and AbbVie ($ABBV) received a similar Overweight reiteration with a price target increase to $303 from $298.

Healthcare Litigation & Settlements

Neutral

Settlement Amount

$670M

Individuals Involved

~2,000
$ABT

Abbott Laboratories ($ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 individuals relating to the company's specialty formulas for preterm infants. The settlement totals approximately $670M. The resolution addresses litigation concerning $ABT's special formulas for pattern infants, representing a significant liability reduction for the healthcare products manufacturer.

Biotech Sector Momentum

Bullish

XBI Gain Since March

34%+34%

Moderna Initial Gain

176.97%+176.97%

Moderna Subsequent Drop

25%-25%
$MRNA$ALVO$XBI

The biotech sector has sustained momentum with the SPDR S&P Biotech ETF up 34% since March, driven by merger and acquisition activity and trial catalysts. Moderna closed up 176.97% following its first-ever Phase 3 win for an mRNA cancer vaccine, though the stock gave back as much as 25% in the following session. Meanwhile, Alvotech ($ALVO) maintained a Hold rating after missing H1 2026 earnings and receiving FDA Complete Response Letters, with the biosimilar pipeline targeting Q4 2026 for key milestones.

Medical Devices & MedTech

Neutral

Stryker Q2 Organic Growth

9%+9%
$ISRG$SYK

Intuitive Surgical ($ISRG) reported Q2/26 results showing the company's competitive moat and recurring revenue model remain intact, though analysts noted the stock's rich valuation warrants a Hold rating. Stryker ($SYK) rebounded with 9% organic growth in Q2 as key segments accelerated, with recent sell-off activity creating what analysts view as a better entry point despite the quarter not being perfect. The medical device sector continues to demonstrate resilient fundamentals amid ongoing growth in surgical robotics and related technologies.

Risk Flags

NoteModerna volatility highlights clinical trial execution risk in biotech sector
WatchConflicting analyst views on Merck suggest uncertain near-term outlook for big pharma

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy

Back to All Briefs